About the Company
kiromic exists to create a robust diagnostic and therapeutic program for solid tumors and hematologic malignancies based on its portfolio of patented cancer-associated biomarkers and small molecules. kiromic aims to develop clinical diagnostic tools for rapid detection of cancer-associated antigens, which may translate into earlier diagnosis and accurate monitoring of response to cancer treatments. our cancer-associated biomarkers also allow for the design and development of personalized, cancer-specific targeted immunotherapy strategies that may improve patient outcomes and result in less suffering and longer survival times.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
50
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KRBP News
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three ...
Kiromic BioPharma, Inc. (KRBP)
HOUSTON, March 01, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second ...
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled ...
Kiromic Biopharma's Deltacel phase 1 shows promise in early lung cancer trial
HOUSTON - Kiromic BioPharma, Inc. (OTCQB: KRBP) has reported preliminary results from its Deltacel-01 Phase 1 clinical trial indicating tumor stabilization in a patient with stage 4 metastatic non ...
Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
Kiromic BioPharma, Inc. (Nasdaq: KRBP) is an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) to develop ...
GT Biopharma Inc GTBP
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
LIXT Lixte Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company that uses biomarker technology to identify enzyme targets associated with serious common diseases.
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 ...
Kiromic Biopharma's Deltacel phase 1 shows promise in early lung cancer trial
HOUSTON - Kiromic BioPharma, Inc. (OTCQB: KRBP) has reported preliminary results from its Deltacel-01 Phase 1 clinical trial indicating tumor stabilization in a patient with stage 4 metastatic ...
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Trial’s Safety Monitoring Committee Recommends Maintaining Initial Cell Dose Level for Next Cohort of Patients Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports ...
Loading the latest forecasts...